Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Bladder Cancer

Clinical Trial at: Texas Oncology - Dallas

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Dallas

A Phase 2, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer (I3Y-MC-JPCM)

  • Details

ClinicalTrials.gov ID: NCT03706365
Diagnosis Type: NA
USOR Number: 18128

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Fallopian Tube Cancer

Clinical Trial at: Texas Oncology - Dallas

Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  • Details

ClinicalTrials.gov ID: NCT03522246
Diagnosis Type: NA
USOR Number: 17182

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Urothelial Cancer

Clinical Trial at: Texas Oncology - Dallas

A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy - SGN22E-001

  • Details

ClinicalTrials.gov ID: NCT03219333
Diagnosis Type: NA
USOR Number: 17005

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Dallas

Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG™) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)

  • Details

ClinicalTrials.gov ID: NCT03596866
Diagnosis Type: NA
USOR Number: 18129

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Ovarian Cancer

Clinical Trial at: Texas Oncology - Dallas

Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  • Details

ClinicalTrials.gov ID: NCT03522246
Diagnosis Type: NA
USOR Number: 17182

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

  • Details

ClinicalTrials.gov ID: NCT03326674
Diagnosis Type: NA
USOR Number: 17009

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Rectal Cancer

Clinical Trial at: Texas Oncology - Dallas

A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM-202)

  • Details

ClinicalTrials.gov ID: NCT03597295
Diagnosis Type: NA
USOR Number: 18134

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Peritoneal Cancer

Clinical Trial at: Texas Oncology - Dallas

Clovis CO-338-087/GOG-3020/ENGOT-ov45/NCRI/ATHENA: A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

  • Details

ClinicalTrials.gov ID: NCT03522246
Diagnosis Type: NA
USOR Number: 17182

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

SYD985.002: A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

  • Details

ClinicalTrials.gov ID: NCT03262935
Diagnosis Type: NA
USOR Number: 17027

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

A Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK3475-KN756)

  • Details

ClinicalTrials.gov ID: NCT03725059
Diagnosis Type: NA
USOR Number: 17188

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Breast Cancer

Clinical Trial at: Texas Oncology - Dallas

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

  • Details

ClinicalTrials.gov ID: NCT03053193
Diagnosis Type: NA
USOR Number: 17079

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lymphomas

Clinical Trial at: Texas Oncology - Dallas

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma - PCYC-1141-CA

  • Details

ClinicalTrials.gov ID: NCT02947347
Diagnosis Type: Non-Hodgkins
USOR Number: 16176

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Dallas

Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non–Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib (2002)

  • Details

ClinicalTrials.gov ID: NCT03535740
Diagnosis Type: NSCLC
USOR Number: 18076

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Myelomas

Clinical Trial at: Texas Oncology - Dallas

C16038: An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Triplet Induction Regimen (Phase IV)

  • Details

ClinicalTrials.gov ID: NCT03173092
Diagnosis Type: NA
USOR Number: 17081

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Myelofibrosis

Clinical Trial at: Texas Oncology - Dallas

INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

  • Details

ClinicalTrials.gov ID: NCT03144687
Diagnosis Type: NA
USOR Number: 17085

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Dallas

TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency (CO-338-063)

  • Details

ClinicalTrials.gov ID: NCT02975934
Diagnosis Type: NA
USOR Number: 16238

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Lung Cancer

Clinical Trial at: Texas Oncology - Dallas

CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

  • Details

ClinicalTrials.gov ID: NCT02869789
Diagnosis Type: NSCLC
USOR Number: 16156

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Prostate Cancer

Clinical Trial at: Texas Oncology - Dallas

TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

  • Details

ClinicalTrials.gov ID: NCT02952534
Diagnosis Type: NA
USOR Number: 16237

  • Practice Details

8196 Walnut Hill Lane, Suite 100
Dallas, Texas 75231
296.45 mi. away
P: (214) 739-4175

More Details View Practice Page

Solid Tumors

Clinical Trial at: Texas Oncology - Mesquite

(INCB 54828-207) A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

  • Details

ClinicalTrials.gov ID: NCT03822117
Diagnosis Type: NA
USOR Number: 19079

  • Practice Details

4700 N Galloway
Mesquite, Texas 75150
298.77 mi. away
P: (972) 686-6411

More Details View Practice Page

Pages